News Archive
Date: 10/17/2012
The University of Michigan Rogel Cancer Center is part of a national organization that has received $11.5 million to study sarcoma, a rare type of cancer that can occur in bones, muscle and fat.
Date: 10/09/2012
Written by Greta Guest; email: [email protected].
Date: 09/25/2012
A new multi-million dollar program at the U-M Rogel Cancer Center will examine how patients make treatment decisions, how doctors make treatment recommendations and how to improve the process for better outcomes.
Date: 09/11/2012
Two different genetic mutations cooperate to induce adrenal cancer, according to a new study from researchers at the University of Michigan Rogel Cancer Center and University of Sao Paulo in Brazil.
Date: 08/30/2012
The Center for the Discovery of New Medicines (CDNM) will coordinate and support work in a range of departments and schools to streamline drug discovery and development, support the translation of early research toward patient use -- a gray area where funding is scarce -- and fully leverage the technical capabilities and intellectual resources at U-M in service of discovering the therapies of tomorrow.
Date: 08/28/2012
MidMichigan Health and the University of Michigan Health System have announced plans to affiliate as clinical and business partners, allowing for a collaboration on the development of a major regional cancer center treating the vast array of cancer diagnoses.
Date: 08/25/2012
The American Cancer Society Cancer Action Network (ACS CAN), the American Cancer Society Great Lakes Division and the University of Michigan Rogel Cancer Center (UMCCC) briefed members of Michigan's congressional delegation today in Ann Arbor to encourage sustained federal funding for cancer research.
Date: 08/24/2012
A research study led by Maha Hussain, MD, associate director of clinical research at the University of Michigan Rogel Cancer Center has found that the survival rate for African American men is now comparable to caucasians when it comes to prostate cancer.
Date: 08/17/2012
As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture, Paradigm, that will help usher in an age of personalized medicine.